Thyroid Nodule (Benign)TArGETNCT07046546
Thyroid Artery Goitre Embolization Trial A Pilot Study Investigating Thyroid Artery Embolisation as a Treatment for Large Thyroid Nodules
A study testing Thyroid artery embolization in people with Thyroid Nodule (Benign) and Graves Disease, run by Royal Berkshire NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
Large non-cancerous thyroid nodules (lumps in the thyroid gland) can cause pressure or discomfort in the neck or cosmetic issues. The standard treatment options include radiofrequency ablation, radioactive iodine, and surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Thyroid Nodule (Benign), Graves Disease, Goitre
- What is being tested?
- Thyroid artery embolization
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 29 Sep 2025to May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The participant may enter the study if ALL of the following apply:
- Adults over 18 years of age willing and able to give informed consent.
- Symptomatic or cosmetically distressing benign nodular thyroid disease with or without intrathoracic extension and with or without hyperthyroidism. Or auto-immune hyperthyroidism (Graves disease).
- Single nodular goitre causing local mass effect warranting treatment or multi-nodular goitre
- TIRADS score 1, 2 and 3 nodules (benign or mildly suspicious) as assessed by ultrasound.
- FNA confirmed benign disease (x2 FNA Thy2 (benign) result required for TR3 nodules, 1x FNA if nodule classified TR2 or less). FNA performed on most high grade nodule or if equal grade then largest nodule.
Show all 9Show fewer
- No enlarged / suspicious neck lymphadenopathy on ultrasound.
- Patient willing to undergo thyroid nodule embolization in preference to other viable treatment options after discussion with Consultant ENT surgeon and / or Consultant Interventional Radiologist. TAE can also be performed as a bridge to surgery, Radiofrequency ablation or Radioactive iodine. Patients may also be unsuitable or unfit for other treatment options.
- Patient able to lay on the angiography table flat with one or two pillows, and can lay comfortably with 30 degrees or less of head elevation for a minimum of two hours.
Who cannot join
- The participant may enter the study if ALL of the following apply:
- Adults over 18 years of age willing and able to give informed consent.
- Symptomatic or cosmetically distressing benign nodular thyroid disease with or without intrathoracic extension and with or without hyperthyroidism. Or auto-immune hyperthyroidism (Graves disease).
- Single nodular goitre causing local mass effect warranting treatment or multi-nodular goitre
- TIRADS score 1, 2 and 3 nodules (benign or mildly suspicious) as assessed by ultrasound.
- FNA confirmed benign disease (x2 FNA Thy2 (benign) result required for TR3 nodules, 1x FNA if nodule classified TR2 or less). FNA performed on most high grade nodule or if equal grade then largest nodule.
Show all 9Show fewer
- No enlarged / suspicious neck lymphadenopathy on ultrasound.
- Patient willing to undergo thyroid nodule embolization in preference to other viable treatment options after discussion with Consultant ENT surgeon and / or Consultant Interventional Radiologist. TAE can also be performed as a bridge to surgery, Radiofrequency ablation or Radioactive iodine. Patients may also be unsuitable or unfit for other treatment options.
- Patient able to lay on the angiography table flat with one or two pillows, and can lay comfortably with 30 degrees or less of head elevation for a minimum of two hours.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Royal Berkshire Hospital
Reading
Ahmad Dr Farhan, +44 1183227936, farhan.ahmad@royalberkshire.nhs.uk
About this study
Official title: Thyroid ARtery Goitre Embolization Trial: A Service Introduction and Safety Assessment
Large non-cancerous thyroid nodules (lumps in the thyroid gland) can cause pressure or discomfort in the neck or cosmetic issues. The standard treatment options include radiofrequency ablation, radioactive iodine, and surgery. Not all patients are suitable however for these treatments, some lumps are too large, or the patients are not fit enough for surgery.
Thyroid artery embolization (TAE) is a new minimally invasive technique (smaller incisions / cuts and shorter recovery time) performed under light sedation. It is used by other European Thyroid Centres, but it hasn't been used in the UK. Embolization means arteries supplying the thyroid gland are blocked by injecting small occlusive particles, like very fine grains of sand that can get stuck in small spaces, preventing blood from passing through. Blocking the thyroid arteries causes the gland to shrink. This provides symptom relief or controls an overactive gland.
We aim to undertake a TAE pilot study to explore the safety of TAE in a UK patient population. We are planning to recruit 10 eligible patients. We will also collect additional data (for example on pain, effectiveness, cost and health related quality of life) to inform a future larger trial comparing TAE to other treatment options.
Read the detailed description
Justification:
Large thyroid nodules in the neck can cause local pressure symptoms and cosmetic issues. Current treatment options include radioactive iodine (RAI), radiofrequency ablation (RFA) and surgery but larger nodules are difficult to shrink or remove and are associated with risks that some patients find unacceptable such as an underactive thyroid gland which requires life long tablets and surgical scars. Larger nodules are also more difficult to remove surgically.
Thyroid artery embolisation (TAE) is a new procedure for non-cancerous thyroid nodules which are causing local symptoms or hyperthyroidism (overactive thyroid glands). TAE involves blocking thyroid arteries using tiny particles introduced via a small tube (catheter). The tube is guided to the thyroid artery under x-ray guidance. In published studies TAE has been used in small numbers of patients with large thyroid glands where other treatment options are difficult. Evidence shows TAE is safe and improves thyroid function in patients with an overactive gland. TAE also causes gland shrinkage (between 40% to 70%) and improves local neck symptoms (like tightness or pressure), cosmetic appearance and quality of life.
Early research indicates TAE is promising but wider use of the procedure is limited by a lack of high-quality research with larger numbers of patients. It has also never been evaluated in the NHS or UK. We therefore aim to undertake the first UK feasibility study into TAE to primarily evaluate safety. This study will help inform a future larger trial to understand how effective TAE is.
Methodology:
Single site study at Royal Berkshire NHS Foundation Trust.
10 patients will be recruited to the study. Participants will have been diagnosed with an enlarged thyroid gland which is causing local neck symptoms (e.g. pressure or tightness), cosmetic issues or thyroid overactivity.
- Patient will be first seen and assessed by the ENT team or Interventional Radiology Consultants who confirm the patient has non-cancerous thyroid nodules and requires treatment for their thyroid disease. This is standard care.
- All patients are then seen by the ENT team (if not already seen). The ENT team consider whether the patient is suitable for study inclusion and discuss possible study participation with the patient. The ENT team provide a study patient information sheet (PIS) and after care advice sheet at this time. With the patients permission the ENT team provides the patients contact details to the research study team (via hospital email or electronic messaging). The ENT team will also document study discussion in the patients electronic records. (10 minutes)
- Study team contacts the patient by telephone and discusses the study. Patient questions addressed. Telephone consent obtained. Patient sent a copy of the consent form prior to their study pre-assessment clinic (by email or paper form by post). (20 minutes) If individuals require more time to consider participation they will be contacted again at an agreed time.
- Potential participants will attend a screening visit in the Interventional Radiology department at RBFT. The following investigations would then be performed / arranged: ultrasound, needle tests of thyroid gland, CT and blood tests. (40 minutes).
- Study team (principle investigator) assesses all results of the screening visit. If the patient meets study inclusion criteria, study team (research nurse) liaises with Radiology booking team and arranges TAE treatment date. Patient and GP informed by letter/email. Patient will be sent a quality of life questionnaire by post or email (30 minutes).
If any results indicate TAE is unsuitable (e.g. abnormal needle test result) the patient will be referred back to the ENT team for standard care.
- Study intervention (TAE) performed. (3 hours which includes arrival, admission and procedure time). (Please note an external expert who is highly experienced in TAE will be present for the first two cases. They will only observe and advise where necessary)
- Patient monitored in Radiology recovery area for 4 hours after procedure (4 hours)
- Patient admitted to ENT ward for overnight observations and then discharged by research team the following day (approximately 16 to 24 hours)
- One week post procedure telephone appointment: Analgesia questionnaire and adverse event score completed (can also be sent by post or email and returned by post or email if required). (30 minutes)
- 3 months post procedure appointment: Quality of life questionnaires; Local symptom and cosmetic scores (out of 10); Thyroid function blood tests; Thyroid volume on ultrasound or CT arranged if required (1h)
- 6 months post procedure appointment: Quality of life questionnaires; Local symptom and cosmetic scores (out of 10); Thyroid function tests; Thyroid volume on ultrasound or CT arrange if required (1h) (Please note clinical assessment / evaluations will be undertaken outside these time points if clinically indicated).
- Conditions
- Thyroid Nodule (Benign), Graves Disease, Goitre
- Being tested
- Thyroid artery embolization
- Keywords
- Thyroid artery embolisation, Benign thyroid nodules
- Medical subject headings
- Thyroid Nodule, Graves Disease, Goiter
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Thyroid artery embolizationProcedure or surgery
Also called TAE
A minimally invasive procedure where one or more thyroid arteries are occluded to shrink the thyroid gland or thyroid nodules
| Study group | Role | What they receive |
|---|---|---|
| Thyroid artery embolization treatment | Experimental | Patient undergoing thyroid artery embolization Receives: Procedure: Thyroid artery embolization |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary outcome measure
To undertake thyroid artery embolisation (TAE) pilot study and make a preliminary (non-powered) evaluation of TAE safety.
The primary end-point is safe treatment with TAE of 10 patients over an 18 month period.
Measured: 18 months
Secondary outcomes (4)
Recruitment
Assess difficulties in recruiting patients by monitoring patient recruitment to time and target
Measured: 18 months
Procedural pain
Procedural pain (Pain score, analgesia use and adverse event recording at 1 week (7 to 10 days).
Measured: 1 week
Procedural outcome
Pre-TAE and 3 and 6 months post TAE: Procedural effectiveness (patient reported symptom and cosmetic scores, thyroid function blood tests, ultrasound (+/-CT assessment) before and at time intervals after TAE).
Pre-TAE and 3 and 6 months post TAE: Health related quality of life impact (Questionnaires before and at time intervals after procedure)
Measured: 3 and 6 month follow up
Cost
At study end: Assess cost effectiveness - analysis by Trust financial analyst will be undertaken
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2025
- Study start29 Sep 2025
- Primary completionNov 2026 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thyroid Nodule (Benign)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Royal Berkshire NHS Foundation Trust
- Sponsor type
- Other government
- Collaborators
- University of Reading
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07046546
- Sponsor's protocol ID
- IRAS338447
- Acronym
- TArGET
- Status last verified
- Dec 2025
- First submitted
- 2 May 2025
- Last updated
- 24 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The investigators aim to disseminate study findings through presentation and publication
Study at a glance
From the registry record, last updated by the sponsor on 24 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Thyroid ARtery Goitre Embolization Trial: A Service Introduction and Safety Assessment
- ClinicalTrials.gov ID
- NCT07046546
- Acronym / sponsor ID
- TArGET / IRAS338447
- Conditions
- Thyroid Nodule (Benign), Graves Disease, Goitre
- Keywords
- Thyroid artery embolisation, Benign thyroid nodules
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Royal Berkshire NHS Foundation TrustOther government
- Collaborators
- University of Reading
- Study start
- 29 Sep 2025 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 1 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Large non-cancerous thyroid nodules (lumps in the thyroid gland) can cause pressure or discomfort in the neck or cosmetic issues. The standard treatment options include radiofrequency ablation, radioactive iodine, and surgery. Not all patients are suitable however for these treatments, some lumps are too large, or the patients are not fit enough for surgery.
Thyroid artery embolization (TAE) is a new minimally invasive technique (smaller incisions / cuts and shorter recovery time) performed under light sedation. It is used by other European Thyroid Centres, but it hasn't been used in the UK. Embolization means arteries supplying the thyroid gland are blocked by injecting small occlusive particles, like very fine grains of sand that can get stuck in small spaces, preventing blood from passing through. Blocking the thyroid arteries causes the gland to shrink. This provides symptom relief or controls an overactive gland.
We aim to undertake a TAE pilot study to explore the safety of TAE in a UK patient population. We are planning to recruit 10 eligible patients. We will also collect additional data (for example on pain, effectiveness, cost and health related quality of life) to inform a future larger trial comparing TAE to other treatment options.
Detailed description
Justification:
Large thyroid nodules in the neck can cause local pressure symptoms and cosmetic issues. Current treatment options include radioactive iodine (RAI), radiofrequency ablation (RFA) and surgery but larger nodules are difficult to shrink or remove and are associated with risks that some patients find unacceptable such as an underactive thyroid gland which requires life long tablets and surgical scars. Larger nodules are also more difficult to remove surgically.
Thyroid artery embolisation (TAE) is a new procedure for non-cancerous thyroid nodules which are causing local symptoms or hyperthyroidism (overactive thyroid glands). TAE involves blocking thyroid arteries using tiny particles introduced via a small tube (catheter). The tube is guided to the thyroid artery under x-ray guidance. In published studies TAE has been used in small numbers of patients with large thyroid glands where other treatment options are difficult. Evidence shows TAE is safe and improves thyroid function in patients with an overactive gland. TAE also causes gland shrinkage (between 40% to 70%) and improves local neck symptoms (like tightness or pressure), cosmetic appearance and quality of life.
Early research indicates TAE is promising but wider use of the procedure is limited by a lack of high-quality research with larger numbers of patients. It has also never been evaluated in the NHS or UK. We therefore aim to undertake the first UK feasibility study into TAE to primarily evaluate safety. This study will help inform a future larger trial to understand how effective TAE is.
Methodology:
Single site study at Royal Berkshire NHS Foundation Trust.
10 patients will be recruited to the study. Participants will have been diagnosed with an enlarged thyroid gland which is causing local neck symptoms (e.g. pressure or tightness), cosmetic issues or thyroid overactivity.
- Patient will be first seen and assessed by the ENT team or Interventional Radiology Consultants who confirm the patient has non-cancerous thyroid nodules and requires treatment for their thyroid disease. This is standard care.
- All patients are then seen by the ENT team (if not already seen). The ENT team consider whether the patient is suitable for study inclusion and discuss possible study participation with the patient. The ENT team provide a study patient information sheet (PIS) and after care advice sheet at this time. With the patients permission the ENT team provides the patients contact details to the research study team (via hospital email or electronic messaging). The ENT team will also document study discussion in the patients electronic records. (10 minutes)
- Study team contacts the patient by telephone and discusses the study. Patient questions addressed. Telephone consent obtained. Patient sent a copy of the consent form prior to their study pre-assessment clinic (by email or paper form by post). (20 minutes) If individuals require more time to consider participation they will be contacted again at an agreed time.
- Potential participants will attend a screening visit in the Interventional Radiology department at RBFT. The following investigations would then be performed / arranged: ultrasound, needle tests of thyroid gland, CT and blood tests. (40 minutes).
- Study team (principle investigator) assesses all results of the screening visit. If the patient meets study inclusion criteria, study team (research nurse) liaises with Radiology booking team and arranges TAE treatment date. Patient and GP informed by letter/email. Patient will be sent a quality of life questionnaire by post or email (30 minutes).
If any results indicate TAE is unsuitable (e.g. abnormal needle test result) the patient will be referred back to the ENT team for standard care.
- Study intervention (TAE) performed. (3 hours which includes arrival, admission and procedure time). (Please note an external expert who is highly experienced in TAE will be present for the first two cases. They will only observe and advise where necessary)
- Patient monitored in Radiology recovery area for 4 hours after procedure (4 hours)
- Patient admitted to ENT ward for overnight observations and then discharged by research team the following day (approximately 16 to 24 hours)
- One week post procedure telephone appointment: Analgesia questionnaire and adverse event score completed (can also be sent by post or email and returned by post or email if required). (30 minutes)
- 3 months post procedure appointment: Quality of life questionnaires; Local symptom and cosmetic scores (out of 10); Thyroid function blood tests; Thyroid volume on ultrasound or CT arranged if required (1h)
- 6 months post procedure appointment: Quality of life questionnaires; Local symptom and cosmetic scores (out of 10); Thyroid function tests; Thyroid volume on ultrasound or CT arrange if required (1h) (Please note clinical assessment / evaluations will be undertaken outside these time points if clinically indicated).
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Thyroid artery embolization treatment | Experimental | Procedure: Thyroid artery embolizationPatient undergoing thyroid artery embolization |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- The participant may enter the study if ALL of the following apply:
Key exclusion criteria (9 listed)
- The participant may enter the study if ALL of the following apply:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Thyroid artery embolizationAlso: TAEA minimally invasive procedure where one or more thyroid arteries are occluded to shrink the thyroid gland or thyroid nodules | Procedure or surgery | Thyroid artery embolization treatment |
Primary outcome
Primary outcome measure
Time frame: 18 months
To undertake thyroid artery embolisation (TAE) pilot study and make a preliminary (non-powered) evaluation of TAE safety. The primary end-point is safe treatment with TAE of 10 patients over an 18 month period.
4 secondary outcomes
Recruitment
Time frame: 18 months
Procedural pain
Time frame: 1 week
Procedural outcome
Time frame: 3 and 6 month follow up
Cost
Time frame: 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Dec 2025.
- Individual participant dataSharing planned: No. The investigators aim to disseminate study findings through presentation and publication
Related trials for Thyroid Nodule (Benign)
Active, not recruiting
Efficacy and Safety of RFA vs MWA for Treatment of Large Benign Thyroid Nodules, RCT
Ablation Techniques, RFA, Ablation Treatment
RecruitingObservational study
Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers
Low Risk, Papillary Thyroid Cancer
Not yet recruitingObservational study
Thyroid Health Outcomes Registry for Surgery
Thyroid Diseases, Thyroid Neoplasms
Recruiting
MWA vs RFA for the Treatment of Moderate-sized Benign Thyroid Nodules
Thyroid Nodule \(Benign\), Ablation Therapy
RecruitingObservational study
Percutaneous Thermo-ablation for the Treatment of Benign Thyroid Nodules
Benign Thyroid Nodule
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Thyroid artery embolization in people with Thyroid Nodule (Benign) and Graves Disease, run by Royal Berkshire NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Farhan Ahmad (+441183227936, farhan.ahmad@royalberkshire.nhs.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary outcome measure (time frame: 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2025.